Clinical Trials Browser

Breast Neoplasms, Neoplastic Cells, Circulating

NCT05360290 2026-02-03

CTCNeoBC-E

Phase NA Recruiting

484 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT06917781 2025-11-18

TAYLOR

Phase NA Recruiting

80 enrolled

Genitourinary

Neoplastic Cells, Circulating, Prostatic Neoplasms

NCT07194616 2025-09-26

Rectal Cancer CTC Trial

Phase NA Recruiting

120 enrolled

Gastrointestinal

Neoplastic Cells, Circulating, Rectal Neoplasms

NCT06904625 2025-08-19

CAPT CTC

Phase NA Recruiting

36 enrolled

BreastGenitourinary

Breast Neoplasms, Neoplastic Cells, Circulating, Prostatic Neoplasms

NCT05133154 2025-07-11

GLIOLIPSY

Phase NA Recruiting

50 enrolled

CNS

Glioma, Neoplastic Cells, Circulating

NCT04581109 2025-07-10

EPIDROP

Phase NA Recruiting

100 enrolled

Genitourinary

Neoplastic Cells, Circulating, Prostatic Neoplasms

NCT05346536 2025-07-10

CTC-AXL-PANC

Phase NA Recruiting

63 enrolled

Gastrointestinal

Neoplastic Cells, Circulating, Pancreatic Neoplasms

NCT06488365 2025-03-11

Cytophone

Phase NA Recruiting

180 enrolled

Dermatologic

Disease, Melanoma, Neoplastic Cells, Circulating, Neoplasm Metastasis

NCT06807502 2025-03-11

PROBE-CTC

Phase NA Recruiting

93 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis

NCT06262386 2024-02-16

Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial

Phase NA Recruiting

358 enrolled

Thoracic

Lung Neoplasms, Neoplastic Cells, Circulating, Recurrence

NCT04782557 2021-03-04

EUS Guided HVA and PVA for Circulating Tumor DNA in Patients

Phase NA Recruiting

60 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Neoplastic Cells, Circulating

Clinical Trials

GALIA

CTCNeoBC-E

TAYLOR

Rectal Cancer CTC Trial

CAPT CTC

GLIOLIPSY

EPIDROP

CTC-AXL-PANC

Cytophone

PROBE-CTC

Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial

EUS Guided HVA and PVA for Circulating Tumor DNA in Patients